]>
IRCT20190903044682N1 IRCT 2019-12-26 Neyshabour University of Medical Sciences statin and inflamation Effect of Atorvastatin versus Rosuvastatin on level of inflammatory markers and low density lipoprotein-cholesterol (LDL) in Patients with acute coronary syndrome: double blind randomize control trial 2019-09-01 anticipated 84 Complete https://irct.ir/trial/41924 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Subjects with inclusion criteria were randomly divided into two groups: atrostatin and rosuvastatin. For this purpose, we randomly divide the participants into atrostatin and simvastatin groups using 4-way randomized blockade. In this study, we will prepare four leaves that are typed on the two leaves of the letter A (atrostatin) and on the other two leaves of the letter R (rosuvastatin) and draw one card for each patient, without the card being drawn. Insert. At the end of each block we have an equal number of people who received treatment A or treatment R. This process continues until the patient has been included in the study as a sample size, Blinding description: In this study, atrovstatin and rosuvastatin are poured into similar envelopes by a secretary and then coded, envelopes are coded, patients are assigned an envelope in order of study, and the envelope code is recorded for each patient. Participants, all researchers, other cardiologists, CCU nurses and cardiologists, laboratory staff, data collectors, patients with phone calls for follow-up, and the Committee on Safety and Data Monitoring, and The person drafting the article is not aware of the contents of the envelopesatment received and face blindness. 3 Levels of inflammatory markers. Intervention 1: Intervention group: atrovastetin is a drug manufactured by Abidi Pharmaceutical Company at a dose of 80 mg once daily after dinner for 60 days. Intervention 2: Intervention group: Rosvastatin is a drug manufactured by Abidi Pharmaceutical Company at a dose of 40 mg once daily after dinner for 60 days. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is No more information
public Seyedeh Samaneh Tabaee
No. 7, Between Farhang 2&4, , Farahbakhsh gharbi, Neyshabour
Neyshabour Iran (Islamic Republic of) 93191169111 0985142255524 tabaees@nums.ac.ir Neyshabour University of Medical Sciences scientific Seyedeh Samaneh Tabaee
No. 7, Between Farhang 2&4, , Farahbakhsh gharbi, Neyshabour
Neyshabour Iran (Islamic Republic of) 9319116911 +98 51 4225 5524 tabaees@nums.ac.ir Neyshabour University of Medical Sciences Iran (Islamic Republic of) Acute coronary syndrome based on clinical signs and ECG and serum markers 18 years 75 years Both renal failure Liver failure Immunosuppressants, corticosteroids or potent inhibitors of cytochrome P450 3A4, pentoxifylline, silostazole, glucosamine, berberine barberry extract Having underlying inflammatory or infectious diseases Left Schiff's Leukostosis TG>400 CHF with NYHA III or IV Having a history of diseases that cause malabsorption syndromes Uncontrolled blood pressure Evidence of endocrine or metabolic disease affecting lipid profile موضوع مطالعه یک بیماری نیست Treatment - Drugs Treatment - Drugs Intervention group: atrovastetin is a drug manufactured by Abidi Pharmaceutical Company at a dose of 80 mg once daily after dinner for 60 days. Intervention group: Rosvastatin is a drug manufactured by Abidi Pharmaceutical Company at a dose of 40 mg once daily after dinner for 60 days. Blood levels of inflammatory markers. Timepoint: Before starting the study and 60 days later beginning. Method of measurement: Laboratory measurement by ELISA. Lipid profile. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory measurement with Pars test kit with Autoanalyzer bt 3000. Blood levels of inflammatory markers. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory tests. Neyshabour University of Medical Sciences Approved 2016-03-09 Ethics committee of Neyshabour University of Medical Sciences University Pardis, Shen Shui Street, Neyshabur Razavi Khorasan Iran (Islamic Republic of)